Clinical Trial Update: Medroxyprogesterone Acetate vs LNG-IUS in Early-stage Endometrioid Carcinoma and Atypical Hyperplasia Patients [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial comparing medroxyprogesterone acetate to LNG-IUS for fertility-sparing management in early-stage endometrioid carcinoma and atypical hyperplasia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hyperplasia of the Endometrium
• Endometrial Cancer

Drugs mentioned

• LNG-IUS (levonorgestrel-releasing intrauterine system)
• Medroxyprogesterone acetate (Medroxyprogesterone acetate)

Snippet

Sponsor: Hua Li | Conditions: Fertility Sparing | Phase 2, Phase 3 | Status: UNKNOWN